EXPAND AND CONSOLIDATE GLOBAL FOOTPRINT

to provide access to quality medicines at an affordable price

Konw More

About IMSDA

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

In The News

Pirfenidone for Post-COVID Pulmonary Fibrosis: 2025–2026 Latest Research & Real Result - New Findings in Pulmonary Fibrosis and Post-COVID Lung Disease Pulmonary fibrosis after COVID-19 is leaving thousands of patients struggling to breathe every day. Many are desperately searching for treatments that can actually slow or stop lung scarring.Pirfenidone, one of the most widely used antifibrotic drugs, has been in the spotlight again with new 2025–2026 research. […]
Latest HIV Treatment Advances and Global Response Challenges (2025) - In 2025, the global fight against HIV has seen both major medical progress and serious challenges, according to recent reports from UNAIDS and the World Health Organization. Dolutegravir-Based Regimens Leading HIV Treatment One of the most significant advancements in HIV care is the widespread adoption of Dolutegravir-based antiretroviral therapy as the preferred first-line treatment worldwide. […]
PAXLOVID – CONDITIONS OF USE - MEDICINAL PRODUCT FOR USE 1. Name of the medicinal product for use: PAXLOVID 2. Active substance(s): Nirmatrelvir and ritonavir 3. Pharmaceutical form: Film-coated tablets 4. Route of administration: Oral use 5. Strength: 150 mg Nirmatrelvir , 100 mg ritonavir
Pfizer boosts Paxlovid manufacturing capacity as Merck’s rival COVID pill hits surprise efficacy setback - The efficacy data for Pfizer’s oral COVID-19 drug now look so appealing that the Big Pharma company is boosting manufacturing capacity even before an expected emergency use authorization from the FDA. Pfizer now expects to make 80 million courses of COVID drug Paxlovid by the end of 2022, Pfizer CEO Albert Bourla told CNBC during […]
Read More

Our Videos

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

Stay Connected

If you have any question,please connect us.

Connect Us

Join Us

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Join Us